Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma

By Hellmann Andrzej  

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 781-791

Adis International

Access to resources Recommend Favorite

Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

By Zhou Shufeng  

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 279-304

Adis International

Access to resources Recommend Favorite

Inhibition and Induction of Cytochrome P450 and the Clinical Implications

By Lin J.H.   Lu A.Y.H.  

Clinical Pharmacokinetics, Vol. 35, Iss. 5, 1998-11 ,pp. : 361-390

Adis International

Access to resources Recommend Favorite

Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4

By Bouillon-Pichault Marion   Jullien Vincent   Bazzoli Caroline   Pons Gérard   Tod Michel  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 38, Iss. 1, 2011-02 ,pp. : 25-40

Springer Publishing Company

Access to resources Recommend Favorite

Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences

By  

Current Drug Metabolism, Vol. 3, Iss. 3, 2002-06 ,pp. : 289-309

Bentham Science Publishers

Access to resources Recommend Favorite